They ran a clinical trial where they accidentally gave a number of patients half a dose. Apparently this was due to lack of validation of an assay by Oxford.
I think the problem is that these "small" issues pop up which just further erodes confidence in the vaccine.
Leaving aside the properties of the vaccine, not keeping promises is a really bad look. Committing to deliver x amount and then delivering .8x without much of an explanation is a sign of bad comms at the very least. And that has not happened once. If you look at how many times AZ has promised to start keeping to the schedule and get their capacity up, the list gets pretty long.
It does not take a management genius to predict, that vaccine deliveries in EU are going to be observed using a microscope and that the moment you flinch, they’ll bite. And AZ flinched.
We’ve all been there. Engineers tell the leadership x is possible, customer demands 2x, leadership bullies engineers into agreeing to deliver on the impossible and in the end it all goes to hell. And that’s a clear leadership failure.